Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P437. The IBD Passport – bridging another gap in quality of care?
P437

Short term prevalence of nodular regenerative hyperplasia of the liver in IBD patients treated with allopurinol-thiopurine combination therapy

Authors:

M. Seinen*1, D. van Asseldonk1, N. de Boer1, G. Bouma1, C. Mulder1, E. Bloemena2, A. van Bodegraven3

1VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2VU University Medical Center, Pathology, Amsterdam, Netherlands, 3ORBIS Medical Center, Internal Medicine, Gastroenterology, and Geriatrics, Sittard, Netherlands

P438.

Intolerance to IBD treatment in over 1,800 patients in the Oxford IBD Cohort

Authors:

A. Kent, H. Gray-Stephens, A.-M. Castaneanu, J. Brooks, P. Siddhanathi, S. Travis, H. Uhlig, S. Keshav, Oxford University Hospitals Trust, Translational Gastroenterology Unit, Oxford, United Kingdom

P438. Differences in the course of ulcerative colitis in patients with primary sclerosing cholangitis
P438. Multicenter prospective observational study to assess the impact of surveillance, prophylaxis or treatment of the hepatitis B (HBV) and C (HCV) virus infection in patients with inflammatory bowel disease (IBD) under anti-TNF therapies
Authors:

C. Loras1, J.P. Gisbert2, C. Saro3, M. Piqueras4, C. Sánchez5, J. Barrio6, I. Ordás7, A. Montserrat8, R. Ferreiro9, F. Fernández-Bañares1, M. Esteve1, 1Hospital Universitari Mútua de Terrassa, Terrassa, Spain, 2Hospital de la Pincesa, Spain, 3Hospital de Cabueñes, Spain, 4Consorci Sanitari de Terrassa, Spain, 5Hospital Universitario La Fe, Spain, 6Hospital Universitario Río Hortega, Spain, 7Hospital Clínic, Spain, 8Hospital del Parc Taulí, Spain, 9Hospital Santiago de Compostela, Spain

P438

Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients

Authors:

M. Chaparro*1, J. Gordillo2, E. Domènech3, M. Esteve4, M. Barreiro de-Acosta5, A. Villoria6, E. Iglesias-Flores7, M. Blasi2, J.E. Naves8, O. Benítez9, L. Nieto5, X. Calvet10, V. García-Sánchez7, J.R. Villagrasa11, A.C. Marín1, M. Ramas1, I. Moreno12, J.P. Gisbert1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, 4Hospital Universitario Mutua de Terrassa, Gastroenterology Unit, Terrassa, Spain, 5Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 6Hospital de Sabadell and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital Universitario Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Barcelona, Spain, 9Hospital Universitario Mutua de Terrassa and CIBERehd. , Gastroenterology Unit, Terrassa, Spain, 10Hospital de Sabadell. Corporació Sanitària Universitària Parc Taulí and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 11Hospital Universitario de La Princesa and IIS-IP , Preventive medicine unit, Madrid, Spain, 12Hospital Universitario de La Princesa and IIS-IP , Fundación de Investigación Biomédica, Madrid, Spain

P439.

In patients with Crohn's disease, timing of switching from infliximab to adalimumab affects prognosis

Authors:

K. Takeuchi, A. Yamada, Y. Suzuki, Toho University, Sakura Medical Centre, Division of Gastroenterology, Department of Internal Medicine, Sakura, Japan

P439. Management and outcome of severe attacks of ulcerative colitis in the era of biologicals
Authors:

J. Llaó1, J.E. Naves2, A. Ruiz-Cerulla3, J. Gordillo1, M. Mañosa4, S. Maisterra3, E. Cabré4, E. Garcia-Planella1, J. Guardiola3, E. Domènech4, 1Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 2Hospital Universitari Germans Trias I Pujol, Dept. of Gastroenterology, Badalona, Spain, 3Hospital Universitari Bellvitge-IDIBELL, Gastroenterology, L'Hospitalet de Llobregat, Spain, 4Hospital Universitari Germans Trias I Pujol-CIBEREHD, Dept. of Gastroenterology, Badalona, Spain

P439. Resource use for patients with Crohn's disease in a Polish tertiary hospital
P439

Deep remission as a predictor of clinical outcomes in vedolizumab-treated patients with ulcerative colitis

Authors:

W. Sandborn*1, J.-F. Colombel2, R. Panaccione3, K. Lasch4, R. Mody5, A. Green6, B. Abhyankar7

1University of California San Diego and UC San Diego Health System, Gastroenterology, San Diego, California, United States, 2Icahn School of Medicine at Mount Sinai Hospital, Gastroenterology, New York, NY, United States, 3University of Calgary, Medicine, Alberta, Canada, 4Takeda Pharmaceuticals International Inc., Medical Affairs, Deerfield, IL, United States, 5Takeda Pharmaceuticals International Inc., Global Outcomes and Epidemiology Research, Deerfield, IL, United States, 6Takeda Global Research & Development Centre (Europe) Ltd., Statistics, London, United Kingdom, 7Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom

P440.

Influence of induction therapy with infliximab on histological changes in children with ulcerative colitis – preliminary data

Authors:

S. Szymanska1, A. Wiernicka2, J. Cielecka-Kuszyk1, E. Szymanska2, M. Dadalski2, J. Kierkus2, 1The Children's Memorial Health Institute, Pathology, Warsaw, Poland, 2The Children's Memorial Health Institute, Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland

P440. Identification of DMBT1 single nucleotide polymorphisms and their haplotypes as novel susceptibility variants for Crohn's disease and ulcerative colitis
P440. Macrocytic anemia secondary to sulphasalazine in patients affected by ulcerative colitis and Crohn's colitis: a real issue?
Authors:

E. Loll1, E. Calabrese1, P. Scarozza1, G. Condino1, M. Ascolani1, S. Onali1, C. Petruzziello1, F. Zorzi1, L. Biancone1, F. Pallone1, 1University of Rome Tor Vergata, GI Unit, Medicine, Rome, Italy

P440

Curcumin add-on therapy for induction of remission in mild-moderate active Ulcerative Colitis: A multi-center, prospective, randomized, double-blind, placebo-controlled trial

Authors:

A. Lang*1, N. Salomon1, J. Wu2, U. Kopylov1, A. Lahat1, O. Har-noi1, J. Ching2, P.K. Cheong2, B. Avidan1, D. Gamus1, I. Kaimakliotis1, R. Eliakim1, S. NG2, S. Ben-Horin1

1Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 2Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, Medicine and Therapeutics, Chinese University of Hong Kong, China

P441.

Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in IBD patients

Authors:

T. van Schaik, R.K. Roopram, P.W. Maljaars, M.H. Verwey, N. Ipenburg, J.C. Hardwick, R.A. Veenendaal, A.E. van der Meulen-de Jong, Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands

P441. Low colectomy rate in treatment refractory ulcerative colitis patients following treatment with the Toll-like receptor 9 agonist DIMS0150
Authors:

E. Musch1, T. Lutfi1, P. von Stein2, A. Zargari2, M. Malek1, T. Knittel2, R. Löfberg3, O. von Stein2, 1Marienhospital, Clinic of Colo-Proctology, Bottrop, Germany, 2InDex Pharmaceuticals, Stockholm, Sweden, 3IBD unit Sophiahemmet and the Dept of Medicine, Karolinska Institutet, Stockholm, Sweden

P441. Whole-genome sequencing, haplotype characterisation and transcriptomic analysis in an extended multiplex kindred with 40 individuals affected with inflammatory bowel disease
P441

Infliximab-Related Infusion Reactions: Systematic Review of Preventive and Management Practices

Authors:

L. Lichtenstein*1, J. Ron2, S. Kivity3, S. Ben-Horin4, E. Israeli5, G. Fraser1, I. Dotan2, Y. Chowers6, R. Confino-Cohen7, B. Weiss8

1Rabin Medical Center, Gastroenterology, Petach Tikva, Israel, 2Tel Aviv Sourasky Medical Center, Gastroenterology, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, Clinical Immunology, Tel Aviv, Israel, 4Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 5Hadassah Medical Center, Gastroenterology, Jerusalem, Israel, 6Rambam Medical Center, Gastroenterology, Haifa, Israel, 7Meir Medical Center, Clinical Immunology, Kfar Saba, Israel, 8Edmond and Lily Safra Children’s Hospital, Gastroenterology, Tel Hashomer, Israel

P442.

Infliximab versus combination infliximab and immunosuppressant therapy for patients with active ulcerative colitis: a meta-analysis

Authors:

D. Christophorou1, N. Funakoshi1, Y. Duny2, J.-C. Valats1, M. Bismuth1, J.-P. Daures2, P. Blanc1, 1University Hospital Saint Eloi, Department of Hepatology and Gastroenterology, Montpellier, France, 2CHU Nimes, Departement d' Information Medicale, Nimes, France

P442. Long-term outcome of treatment with infliximab in patients with steroid-dependent ulcerative colitis
Authors:

A. Armuzzi1, D. Pugliese1, S. Danese2, G. Rizzo1, M. Marzo1, C. Felice1, G. Andrisani1, G. Fiorino2, O.M. Nardone1, I. De Vitis1, A. Papa1, G.L. Rapaccini1, L. Guidi1, 1Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy, 2IBD Unit, Istituto Clinico Humanitas, Rozzano, Italy